ArticleBritish journal of clinical pharmacology2012
Unlicensed use of metformin in children and adolescents in the UK.
Article in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016Pooled it
- Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.Nature medicine · 2020Trial
- Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial.Nutrition & diabetes · 2016Trial
- Pediatric Medication Noninitiation in Spain.Pediatrics · 2022Observational
- Adolescent polycystic ovary syndrome according to the international evidence-based guideline.BMC medicine · 2020Article
- Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment.International journal of endocrinology and metabolism · 2019Review
- Widding the Use of Insulin Sensitizers to Patients with Polycystic Ovarian Syndrome-A Late, but Wise Decision.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2019Article
- Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity.Obesity (Silver Spring, Md.) · 2019Review
- Interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews.International journal of obesity (2005) · 2018Review
- Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges.Adolescent health, medicine and therapeutics · 2017Review
- Time course, outcome and management of adverse drug reactions associated with metformin from patient's perspective: a prospective, observational cohort study in the Netherlands.European journal of clinical pharmacology · 2016Observational
- Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands.British journal of clinical pharmacology · 2015Article
- No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study.BMC public health · 2014Article
- Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes.Paediatric drugs · 2014Article
- Unlicensed use of metformin in children and adolescents in Germany and France.British journal of clinical pharmacology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
aimMetformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0-18 years in the UK.
methodsPopulation-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010.
resultsA total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P= 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n= 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n= 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only.
conclusionsPrescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.